Axsome Therapeutics, Inc. (AXSM)Healthcare | Biotechnology | New York, United States | NasdaqGM
199.02 USD
-7.25
(-3.515%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 199.00 -0.02 (-0.020%) ⇩ (Aug. 28, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:04 a.m. EDT
Axsome Therapeutics offers a compelling long-term thesis anchored by explosive revenue growth and a net-cash balance sheet, though the lack of profitability keeps the short-term outlook cautious. The stock trades below its fifty-day average but holds above the two-hundred-day average, signaling a consolidation phase before the upcoming earnings report. While the statistical forecast leans neutral, the options market is pricing in significant moves with heavy positioning at both upside targets and downside protection. Investors should view this as a high-conviction growth play where the balance sheet provides a safety net, but earnings per share remain negative until commercialization scales. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.065624 |
| AutoETS | 0.065641 |
| MSTL | 0.066080 |
| AutoTheta | 0.134809 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 18.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.148 |
| Excess Kurtosis | -1.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 269.727 |
| Revenue per Share | 15.251 |
| Market Cap | 10,424,829,952 |
| Forward P/E | 39.54 |
| Beta | 0.73 |
| Profit Margins | -24.68% |
| Website | https://www.axsome.com |
As of Aug. 22, 2026, 4:04 a.m. EDT: Speculators are positioning for high volatility with implied volatility hovering around 50 to 60 percent. Open interest is concentrated at out-of-the-money calls targeting prices above 270, indicating bullish bets on upside potential, while put open interest clusters at lower strikes between 130 and 145, suggesting hedging or contrarian views on downside risk. Recent flow shows increased call volume at the 220 strike for December expiration, hinting at a near-term directional bias toward the upside despite the elevated premium.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6706083 |
| Address1 | One World Trade Center |
| Address2 | 29th Floor |
| All Time High | 260.19 |
| All Time Low | 1.94 |
| Ask | 259.2 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 541,160 |
| Average Daily Volume3 Month | 861,974 |
| Average Volume | 861,974 |
| Average Volume10Days | 541,160 |
| Beta | 0.726 |
| Bid | 170.52 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.593 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 199.02 |
| Current Ratio | 1.426 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 205.7 |
| Day Low | 199.0 |
| Debt To Equity | 269.727 |
| Display Name | Axsome Therapeutics |
| Earnings Call Timestamp End | 1,786,363,200 |
| Earnings Call Timestamp Start | 1,786,363,200 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | -172,919,008 |
| Ebitda Margins | -0.22267 |
| Enterprise To Ebitda | -59.737 |
| Enterprise To Revenue | 13.302 |
| Enterprise Value | 10,329,673,728 |
| Eps Current Year | -2.63666 |
| Eps Forward | 5.03398 |
| Eps Trailing Twelve Months | -3.75 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 320 0245 |
| Fifty Day Average | 228.6054 |
| Fifty Day Average Change | -29.585388 |
| Fifty Day Average Change Percent | -0.12941684 |
| Fifty Two Week Change Percent | 67.06083 |
| Fifty Two Week High | 260.19 |
| Fifty Two Week High Change | -61.17 |
| Fifty Two Week High Change Percent | -0.23509742 |
| Fifty Two Week Low | 112.9 |
| Fifty Two Week Low Change | 86.12 |
| Fifty Two Week Low Change Percent | 0.76279896 |
| Fifty Two Week Range | 112.9 - 260.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,447,943,400,000 |
| Float Shares | 44,462,410 |
| Forward Eps | 5.03398 |
| Forward P E | 39.53532 |
| Free Cashflow | -4,581,750 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,346 |
| Fullday Change | -7.25 |
| Fullday Change Percent | -3.51481 |
| Fullday Price | 199.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.93236 |
| Gross Profits | 724,038,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15082 |
| Held Percent Institutions | 0.7459 |
| Implied Shares Outstanding | 52,380,818 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York. |
| Long Name | Axsome Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 10,424,829,952 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_241907563 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -191,644,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,796,210,397 |
| Number Of Analyst Opinions | 21 |
| Open | 205.7 |
| Operating Cashflow | -71,259,000 |
| Operating Margins | -0.23419 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 212 332 3241 |
| Post Market Change | -0.020004272 |
| Post Market Change Percent | -0.010051387 |
| Post Market Price | 199.0 |
| Post Market Time | 1,787,960,889 |
| Previous Close | 206.27 |
| Price Eps Current Year | -75.48186 |
| Price Hint | 2 |
| Price To Book | 124.93408 |
| Price To Sales Trailing12 Months | 13.424215 |
| Profit Margins | -0.24678 |
| Quick Ratio | 1.297 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2381 |
| Region | US |
| Regular Market Change | -7.25 |
| Regular Market Change Percent | -3.51481 |
| Regular Market Day High | 205.7 |
| Regular Market Day Low | 199.0 |
| Regular Market Day Range | 199.0 - 205.7 |
| Regular Market Open | 205.7 |
| Regular Market Previous Close | 206.27 |
| Regular Market Price | 199.02 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 441,176 |
| Return On Assets | -0.16312 |
| Return On Equity | -2.45102 |
| Revenue Growth | 0.455 |
| Revenue Per Share | 15.251 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 52,380,818 |
| Shares Percent Shares Out | 0.0612 |
| Shares Short | 3,205,664 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,024,030 |
| Short Name | Axsome Therapeutics, Inc. |
| Short Percent Of Float | 0.0949 |
| Short Ratio | 4.37 |
| Source Interval | 15 |
| State | NY |
| Symbol | AXSM |
| Target High Price | 380.0 |
| Target Low Price | 246.0 |
| Target Mean Price | 285.41953 |
| Target Median Price | 280.0 |
| Total Cash | 319,849,984 |
| Total Cash Per Share | 6.106 |
| Total Debt | 224,692,992 |
| Total Revenue | 776,569,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 192.8083 |
| Two Hundred Day Average Change | 6.2117004 |
| Two Hundred Day Average Change Percent | 0.032216977 |
| Type Disp | Equity |
| Volume | 441,176 |
| Website | https://www.axsome.com |
| Zip | 10,007 |